Citations

Clear

7 citation(s) found for "Pitt, Bertram".

Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post‐Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest
Danesh, Sina , Khan, Fazal , Chopko, Trevor C. , Lee, Aurora , Huo, Ran , Shuyang, Lu, Tam, Vincy , Gao, Wenbin , Todd, Austin , Maleszewski, Joseph J. , Chen, Y. Eugene , Friedman, Paul A. , Oral, Hakan , Metra, Marco , Pitt, Bertram, Lei, Ienglam , Chopko, Trevor , Lu, Shuyang, Pagani, Francis D , Schaff, Hartzell , Chen, Y Eugene , Friedman, Paul A , Oral, Hakan , Pitt, Bertram , Tang, Paul C , Khan, Fazal Wahab , Metra, Marco , Huo, Ran, Tam, Vincy , Safi, J. Pedro , Todd, Austin, Pagani, Francis D. , Schaff, Hartzell V. , Pitt, Bertram , Tang, Paul C.

Mayo Clinic

Journal of the American Heart Association | October 9, 2025 | Volume: 14 | Issue: 20 | Pages: No page available

10.1161/jaha.125.043661 | PMID 41065249 Get It

Background Postoperative atrial fibrillation occurs in ~40% after cardiac surgery. Mineralocorticoid receptor antagonists (MRA) are known to reduce chronic atrial fibrillation (AF) development and burden. We evaluated the association of preoperative MRA use with postoperative atrial fibrillation and investigated atrial cell types modulated by MRAs during cold preservation. Methods We studied 19 042 cardiac surgery patients at Mayo Clinic. Propensity 1:3 matching identified 298 MRA users and 894 non‐users. A subgroup analysis of patients on any preoperative diuretic was performed to isolate cardiac‐specific effects of MRAs, matching 298 MRA users to 894 non‐MRA diuretic users. AF recurrence was assessed for up to 6‐years. Single‐nucleus RNA sequencing (snRNA‐seq) was performed on human donor atria exposed to canrenone (a water‐soluble MRA) during cold preservation with ex‐vivo reperfusion, and expression profiles were compared with atria from patients with AF. Results After matching, preoperative MRA use was associated with a lower incidence of postoperative atrial fibrillation (19.8% versus 31.8%, P <0.001). In the diuretic‐only subgroup, MRA users also had lower postoperative atrial fibrillation (19.8% versus 33.2%, P <0.001). MRA use was associated with a reduced incidence of paroxysmal and chronic AF at 6‐years. snRNA‐seq identified a cardiomyocyte subpopulation, CM2, with high mineralocorticoid receptor expression where canrenone suppressed cold preservation‐induced mineralocorticoid receptor target gene expression, which was conversely elevated in chronic AF. Canrenone also attenuated stress‐response in atrial macrophages and pericytes. Conclusions Preoperative MRAs were associated with reduced postoperative and long‐term AF after cardiac surgery. Mechanistically, our ex‐vivo human atrial model revealed that MRAs suppress mineralocorticoid receptor ‐driven atrial stress responses, particularly in conduction‐relevant cardiomyocytes.
Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post-Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest
Danesh, Sina , Khan, Fazal , Lee, Aurora , Huo, Ran , Shuyang, Lu, Tam, Vincy, Safi, J. Pedro , Maleszewski, Joseph J. , Friedman, Paul A. , Oral, Hakan , Metra, Marco , Pitt, Bertram, Safi, Pedro Fincatto , Pagani, Francis D , Maleszewski, Joseph J , Schaff, Hartzell , Friedman, Paul A , Oral, Hakan , Pitt, Bertram , Tang, Paul C , Khan, Fazal Wahab , Metra, Marco , Chopko, Trevor C. , Huo, Ran, Tam, Vincy , Gao, Wenbin , Todd, Austin, Pagani, Francis D. , Schaff, Hartzell V. , Lei, Ienglam , Tang, Paul C.

Mayo Clinic

No container title available | February 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.02.24.639999 | PMID 40060465 Get It

Abstract Background New postoperative atrial fibrillation (POAF) occurs in about 40% after cardiac surgery. Mineralocorticoid receptor antagonists (MRA) are known to reduce chronic atrial fibrillation (AF) development and burden. We examined the impact of preoperative MRA use on POAF and also examine the atrial cell type impacted by MRA treatment during cold cardiac preservation. Methods Retrospective study of 19,042 patients who underwent cardiac surgery at Mayo Clinic in Minnesota, and performed 1:3 propensity matching to obtain 298 patients on preoperative MRA matched to 894 who were not. We also separately matched patients using preoperative diuretics. Single-nuclei RNA sequencing (snRNA-seq) examined MRA’s effects on different atrial cell types in canrenone (water soluble MRA) treated human donor hearts undergoing cold preservation followed by ex-vivo reperfusion and compared gene expression to the atria of patients with AF. Results Propensity matched preoperative MRA group had less new onset POAF (19.8% vs 31.5%, P<0.001). To account for the possibility that preoperative diuretic use and volume reduction may impact POAF, we propensity matched 298 preop diuretic users that included MRA use to another 894 patients who used a non-MRA diuretic preoperatively. Those who used preoperative MRA similarly had a lower incidence of POAF (19.8% vs 33.2%, P<0.001). No survival difference was present between the propensity matched groups that used preoperative diuretics (P=0.079). Preoperative MRA use also reduced the development of paroxysmal and chronic AF at 6 years of follow up. From our snRNA-seq data, we identified a subpopulation of atrial cardiomyocytes (CM2) that had high MR expression where canrenone suppressed the increase in MR target gene expression associated with cold preservation-reperfusion. These MR targets were conversely elevated in patients with chronic AF. Canrenone also suppressed other cardiac preservation associated genes that show elevated expression in atrial macrophages and pericytes from chronic AF atria. Conclusions Our studies show that preoperative MRA use is associated with 40% reduction in POAF as well as lowering long standing AF development by about 41%. Our cold cadiac preservation-reperfusion model showed that canrenone reduced expression of MR target genes associated with chronic AF, particular in cardiomyocytes with important roles in electrical conduction. Clinical Perspective What is New? This study shows that preoperative use of mineralocorticoid receptors antagonists (MRA) is associated with a reduced incidence of new onset perioperative atrial fibrillation after cardiac surgery utilizing cardiopulmonary bypass. We show that preoperative MRA use is associated with a lower incidence of developing more chronic paroxymal or sustained atrial fibrillation. Addition of canrenone, a clinically utilized water soluble MRA, to cardioplegia solution used during cardiac preservation can attenuate atrial inflammatory reponses and reduce signaling through molecular pathways that promote atrial fibrillation. What are the clinical implications? Perioperative use of MRAs may be considered to reduce early postoperative atrial fibrillation as well as lowering the risk of developing more chronic atrial arrhythmias. These findings support pursuing a clinical trial to determine the impact of MRA use on atrial arrhythmias following cardiac surgery in the setting of cardiopulmonary bypass with cold cardiac preservation.
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials
Nassif, Michael E. , Windsor, Sheryl L. , Gosch, Kensey , Borlaug, Barry A. , Husain, Mansoor , Inzucchi, Silvio E. , Kitzman, Dalane W. , McGuire, Darren K. , Scirica, Benjamin M. , Austin, Bethany A. , Lamba, Sumant, Khumri, Taiyeb, Kosiborod, Mikhail , Scirica, Benjamin M , Shah, Sanjiv J , Austin, Bethany A , Sharma, Kavita , Kosiborod, Mikhail N , Borlaug, Barry A , Windsor, Sheryl L , Husain, Mansoor , McGuire, Darren K , Pitt, Bertram , Umpierrez, Guillermo E. , Sharma, Kavita

Mayo Clinic

Circulation: Heart Failure | May 19, 2023 | Volume: 16 | Issue: 7 | Pages: No page available

10.1161/circheartfailure.122.009837 | PMID 37203441 Get It

BACKGROUND: Patients with heart failure (HF) have a high burden of symptoms and physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 (sodium-glucose cotransporter-2) inhibitors on these outcomes vary across the full range of EF remains unclear. METHODS: Patient-level data were pooled from the DEFINE-HF trial (Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction) of 263 participants with reduced EF (≤40%), and PRESERVED-HF trial (Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients With Preserved Ejection Fraction Heart Failure) of 324 participants with preserved EF (≥45%). Both were randomized, double-blind 12-week trials of dapagliflozin versus placebo, recruiting participants with New York Heart Association class II or higher and elevated natriuretic peptides. The effect of dapagliflozin on the change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) at 12 weeks was tested with ANCOVA adjusted for sex, baseline KCCQ, EF, atrial fibrillation, estimated glomerular filtration rate, and type 2 diabetes. Interaction of dapagliflozin effects on KCCQ-CSS by EF was assessed using EF both categorically and continuously with restricted cubic spline. Responder analyses, examining proportions of patients with deterioration, and clinically meaningful improvements in KCCQ-CSS were conducted using logistic regression. RESULTS: Of 587 patients randomized (293 dapagliflozin, 294 placebo), EF was ≤40, >40-≤60, and >60% in 262 (45%), 199 (34%), and 126 (21%), respectively. Dapagliflozin improved KCCQ-CSS at 12 weeks (placebo-adjusted difference 5.0 points [95% CI, 2.6–7.5]; P <0.001). This was consistent in participants with EF≤40 (4.6 points [95% CI, 1.0–8.1]; P =0.01), >40 to ≤60 (4.9 points [95% CI, 0.8–9.0]; P =0.02) and >60% (6.8 points [95% CI, 1.5–12.1]; P =0.01; P interaction =0.79). Benefits of dapagliflozin on KCCQ-CSS were also consistent when analyzing EF continuously ( P interaction =0.94). In responder analyses, fewer dapagliflozin-treated patients had deterioration and more had small, moderate, and large KCCQ-CSS improvements versus placebo; these results were also consistent regardless of EF (all P interaction values nonsignificant). CONCLUSIONS: In patients with HF, dapagliflozin significantly improves symptoms and physical limitations after 12 weeks of treatment, with consistent and clinically meaningful benefits across the full range of EF. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT02653482 and NCT03030235.
Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure
Rafique, Zubaid , Weir, Matthew R. , Lafayette, Richard , Butler, Javed , Farnum, Carolyn, Onuigbo, Macaulay , Pitt, Bertram , Lopes, Maria Carolina Barbosa Teixeira , Peacock, William Frank

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | May 9, 2017 | Volume: 23 | Issue: 4-a Suppl | Pages: S10-S19

10.18553/jmcp.2017.23.4-a.s10 | PMID 28485203 Get It

Myocardial Infarction and Cardiac Mortality in the Bypass Angioplasty Revascularization Investigation (BARI) Randomized Trial
Rosen, Allan D., Williams, David O., Aguirre, Frank V. , Rautaharju, Pentti M., Rogers, William J. , Sharaf, Barry L., Hardison, Regina M., Srivatsa, Sanjay S. , Kouchoukos, Nicholas T. , Detre, Katherine M., Frye, Robert L. , Chaitman, Bernard , Bourassa, Martial G. , Pitt, Bertram , Attubato, Michael , Stocke, Karen S. , Sopko, George S.

Mayo Clinic

Circulation | June 12, 2012 | Volume: 96 | Issue: 7 | Pages: 2162-2170

10.1161/01.cir.96.7.2162 | PMID 9337185 Get It

Background Cardiac mortality and myocardial infarction (MI) rates are used to evaluate the efficacy of coronary artery bypass grafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA). We compared 5-year cardiac mortality and MI rates in 1829 patients with multivessel disease randomized to CABG or PTCA. Methods and Results The 5-year cardiac mortality rate was 8.0% in patients assigned to PTCA compared with 4.9% in those assigned to CABG (relative risk [RR] of 1.55 with a 95% confidence interval [CI] of 1.07 to 2.23; P =.022). In a subgroup of 1476 nondiabetic patients, there were no significant differences between treatment groups in cardiac mortality either overall (4.6% versus 4.2%; RR=1.04, 95% CI, 0.65 to 1.66; P =.908) or in subgroups based on symptoms, left ventricular function, number of diseased vessels, or stenotic proximal left anterior descending artery. The two treatment groups had similar event rates for the combined end point of cardiac death or MI. The RR for cardiac mortality in 264 patients who sustained an MI compared with those who did not was 5.9 ( P <.001). MIs were more common after CABG during index hospitalization ( P =.004), but in the PTCA group, they were more common after discharge ( P <.001). Conclusions The Bypass Angioplasty Revascularization Investigation (BARI) trial indicates 5-year cardiac mortality in patients with multivessel disease was significantly greater after initial treatment with PTCA than with CABG. The difference was manifest in diabetic patients on drug therapy. There were no significant differences overall for the composite end point of cardiac mortality or MI between treatment groups or for cardiac mortality in nondiabetic patients regardless of symptoms, left ventricular function, number of diseased vessels, or stenotic proximal left anterior descending artery.
Medical Costs and Quality of Life 10 to 12 Years After Randomization to Angioplasty or Bypass Surgery for Multivessel Coronary Artery Disease
Hlatky, Mark A. , Boothroyd, Derek , Melsop, Kathryn , Brooks, Maria M. , Mark, Daniel B. , Pitt, Bertram, Reeder, Guy S., Rogers, William J. , Ryan, Thomas J. , Whitlow, Patrick L., Wiens, Robert D., Mark, Daniel B

Mayo Clinic

Circulation | September 28, 2004 | Volume: 110 | Issue: 14 | Pages: 1960-1966

10.1161/01.cir.0000143379.26342.5c | PMID 15451795 Get It

Background— Coronary bypass surgery (CABG) and angioplasty (PTCA) have been compared in several randomized trials, but data about long-term economic and quality-of-life outcomes are limited. Methods and Results— Cost and quality-of-life data were collected prospectively from 934 patients who were randomized in the Bypass Angioplasty Revascularization Investigation (BARI) and followed up for 10 to12 years. CABG had 53% higher costs initially, but the gap closed to <5% during the first 2 years; after 12 years, the mean cumulative cost of CABG patients was $123 000 versus $120 750 for PTCA, yielding a cost-effectiveness ratio of $14 300/life-year added. CABG patients experienced significantly greater improvement in their physical functioning for the first 3 years but not in later follow-up. Recurrent angina substantially reduced all quality-of-life measures throughout follow-up. Cumulative costs were significantly higher among patients with diabetes, heart failure, and comorbid conditions and among women; costs also were increased by angina, by the number of revascularization procedures, and among patients who died. Conclusion— Early differences between CABG and PTCA in costs and quality of life were no longer significant at 10 to 12 years of follow-up. CABG was cost-effective as compared with PTCA for multivessel disease.